TGFB1 and hepatocellular carcinoma: In a Phase II study [116] of pembrolizumab for HCC by Lynn et al., high baseline plasma TGF-B levels (≥200 pg/mL) were significantly correlated with poor treatment outcomes after pembrolizumab treatment.